McKesson Corporation MCK
Composite 54/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 36/100 — a moderate mark against it.
Growth ranks 71/100 — a moderate point in its favour. Momentum ranks 63/100 — a moderate point in its favour. Balance-sheet strength ranks 55/100 — a slight point in its favour.
Income ranks 36/100 — a moderate mark against it. Quality ranks 44/100 — a slight mark against it.
What the company does McKesson Corporation (MCK) is a large U.S.-based medical distributor and healthcare services provider, operating in pharmaceutical distribution, oncology, medical-surgical supplies, and technology solutions for pharmacies and providers.
Key financials Revenue grew 12% and EPS rose 41% year-over-year. Margins are thin: gross 3.6%, operating 1.4%, net 1.1%. ROE is 0% and ROA is 4.7%. Debt/Equity is negative 2.76 with net debt/EBITDA at 0.94.
Stock health SideraVista scores the stock Weak quality overall (54.2/100), with Strength 55.0, Growth 72.8, and Valuation 53.1. Momentum is mixed: +31.81% over 12 months but -5.28% over 6 months.
Price vs fair value MCK trades at a discount of 9.50% versus the analyst mean target of 991.40. - Recent acquisition of Precision Medicine Group for $2.25B (Quartz; MT Newswires; Benzinga) signals strategic expansion. - Raised FY27 guidance as oncology and GLP-1 growth accelerate (Zacks). - Sector update highlights healthcare strength amid broader market volatility (MT Newswires).
Looking forward Forward P/E is 19.76 and PEG is 1.02, suggesting moderate valuation relative to growth. Clinical research expansion and guidance optimism may support sentiment, but thin margins and weak quality scores warrant caution.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.